IMNM Q1 2025 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+184.4% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$45M-1525.5% margin

Net Income

-$42M-1423.1% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+6.9%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$57M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$343M

Total Liabilities

$36M

Stockholders' Equity

$307M

Cash & Equivalents

$258M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+184.4%
Gross Profit	$3M	$1M	+184.4%
Operating Income	-$45M	-$132M	+66.3%
Net Income	-$42M	-$129M	+67.8%